Martin Gebel

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America

Predictive value of venous thromboembolism (<scp>VTE</scp>)‐<scp>BLEED</scp> to predict major bleeding and other adverse events in a practice‐based cohort of patients with <scp>VTE</scp>: results of the <scp>XALIA</scp> study

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE